Mastocytosis

被引：1

作者：

Gumusburun, Reyhan ^{[1
]}

Musabak, Ugur Haci ^{[2
]}

Bavbek, Sevim ^{[1
]}

机构：

[1] Ankara Univ, Sch Med, Dept Immunol & Allergy Dis, Ankara, Turkey

[2] Baskent Univ, Ankara Hosp, Dept Immunol & Allergy, Ankara, Turkey

来源：

ASTIM ALLERJI IMMUNOLOJI | 2019年 / 17卷 / 03期

关键词：

Mast cell; mastocytosis; mast cell activation syndrome (MCAS); triptase; anaphylaxis; CELL ACTIVATION SYNDROMES; SYSTEMIC MASTOCYTOSIS; TREATMENT OPTIONS; MAST; ANAPHYLAXIS; OMALIZUMAB; CLASSIFICATION; DISORDERS; TRYPTASE; EFFICACY;

D O I：

10.21911/aai.461

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

Mast cell activation diseases are common as either atopic diseases or rarely occur as mastocytosis and mast cell activation syndrome. Mastocytosis is a clonal disorder characterized by proliferation and accumulation of mast cells in various tissues, particularly the skin and bone marrow. Mast cell activation syndrome is characterized by systemic symptoms ranging from flushing and abdominal cramps to anaphylaxis secondary to mast cell degranulation. The aim of this review was to increase the awareness of the clinical features, classification, diagnosis, and treatment approaches of systemic mastocytosis. In addition, the role of mast cell activation syndrome in the differential diagnosis will be discussed.

引用

页码：119 / 128

页数：10

共 45 条

[1] Disease spectrum in patients with elevated serum tryptase levels [J].

Aberer, Elisabeth ;

Savic, Sandra ;

Bretterklieber, Agnes ;

Reiter, Harald ;

Berghold, Andrea ;

Aberer, Werner .

AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2015, 56 (01) :7-13

[2] Mast cell activation syndromes [J].

Akin, Cem .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2017, 140 (02) :349-355

[3] Mast cell activation syndrome: Proposed diagnostic criteria [J].

Akin, Cem ;

Valent, Peter ;

Metcalfe, Dean D. .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2010, 126 (06) :1099-U60

[4] Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms [J].

Alvarez-Twose, Ivan ;

Gonzalez de Olano, David ;

Sanchez-Munoz, Laura ;

Matito, Almudena ;

Esteban-Lopez, Maria I. ;

Vega, Arantza ;

Belen Mateo, Maria ;

Alonso Diaz de Durana, Maria D. ;

de la Hoz, Belen ;

del Pozo Gil, Maria D. ;

Caballero, Teresa ;

Rosado, Ana ;

Sanchez Matas, Isabel ;

Teodosio, Cristina ;

Jara-Acevedo, Maria ;

Mollejo, Manuela ;

Garcia-Montero, Andres ;

Orfao, Alberto ;

Escribano, Luis .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2010, 125 (06) :1269-1278

[5]

[Anonymous], 1869, Br Med J, V2, P323

[6]

[Anonymous], 2017, BLOOD S1

[7] The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia [J].

Arber, Daniel A. ;

Orazi, Attilio ;

Hasserjian, Robert ;

Thiele, Jurgen ;

Borowitz, Michael J. ;

Le Beau, Michelle M. ;

Bloomfield, Clara D. ;

Cazzola, Mario ;

Vardiman, James W. .

BLOOD, 2016, 127 (20) :2391-2405

[8]

Bonadonna P, 2014, J INVEST ALLERG CLIN, V24, P288

[9] Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: Efficacy and safety observations [J].

Broesby-Olsen, S. ;

Vestergaard, H. ;

Mortz, C. G. ;

Jensen, B. ;

Havelund, T. ;

Hermann, A. P. ;

Siebenhaar, F. ;

Moller, M. B. ;

Kristensen, T. K. ;

Bindslev-Jensen, C. .

ALLERGY, 2018, 73 (01) :230-238

[10] Mast Cell Activation Syndrome and Mastocytosis: Initial Treatment Options and Long-Term Management [J].

Castells, Mariana ;

Butterfield, Joseph .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2019, 7 (04) :1097-1106

← 1 2 3 4 5 →